Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region

NCT07548346 is registered in ClinicalTrials.gov with Middle East North Africa Stroke and Interventional Neurotherapies Organization as lead sponsor.

NCT NCT07548346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07548346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region
Lead sponsor
Middle East North Africa Stroke and Interventional Neurotherapies Organization
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
January 31, 2030
Enrollment
440 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral venous sinus thrombosis